WO1992005246A1 - Medium for culture of mammalian cells - Google Patents

Medium for culture of mammalian cells Download PDF

Info

Publication number
WO1992005246A1
WO1992005246A1 PCT/US1991/006837 US9106837W WO9205246A1 WO 1992005246 A1 WO1992005246 A1 WO 1992005246A1 US 9106837 W US9106837 W US 9106837W WO 9205246 A1 WO9205246 A1 WO 9205246A1
Authority
WO
WIPO (PCT)
Prior art keywords
per liter
medium
milligrams per
serum
amount
Prior art date
Application number
PCT/US1991/006837
Other languages
French (fr)
Inventor
Luciano Ramos
Amy Anne Murnane
Melvin Susumu Oka
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to AU87348/91A priority Critical patent/AU662491B2/en
Publication of WO1992005246A1 publication Critical patent/WO1992005246A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0037Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/24Iron; Fe chelators; Transferrin
    • C12N2500/25Insulin-transferrin; Insulin-transferrin-selenium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/34Sugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/36Lipids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/74Undefined extracts from fungi, e.g. yeasts

Definitions

  • the present invention relates to the field of cell culture media. More particularly the invention relates to the field of mammalian cell culture media. Background of the Invention
  • serum-free media Beyond a basal nutrient mixture of salts, sugars, amino acids, and vitamins, cells .in vitro have also been found to require for proliferation a supplement of poorly defined biological fluids or extracts. Because of availability and ease of storage, the most commonly used supplement is serum.
  • the use of serum in cell culture media has several disadvantages. Serum is comparatively expensive. Since serum is not a defined component, different lots of serum may vary in the concentration of compounds present and thus result in unpredictable culture growth. Serum may also be contaminated with viruses or mycoplasms. The protein in serum may complicate the purification of cell products from the culture medium. In efforts to overcome the disadvantages of serum containing medium, researchers have attempted to provide serum-free media by substituting defined or better characterized components for serum.
  • U.S. Patent 4,786,599 issued November 22, 1988 to Chessebeuf and Padieu discloses a serum-free animal tissue culture medium containing a mixture of six fatty acids and albumin or dextran.
  • the medium is particularly adapted for the primary culture of rat liver epithelial cells and possibly in the presence of hormones and/or growth factors, for obtaining cell lines, in particular myeloma and hybridoma cell lines.
  • Cytobiologica 2_6 123-132 report a serum-free medium for the culture of chick embryo cells containing dextran.
  • Pietrzkowski and Korohoda (1988) Folia Histochemica et Cytobiologica _ ⁇ 143-154 report a serum-free medium containing dextran for the culture of chick embryo fibroblasts. In these two publications, the dextran was added to the medium to enhance cell attachment and spreading.
  • Ohmori (1988) Journal of Immunological Methods 112: 227-233 reports a serum-free medium which is able to support primary antibody responses by cultured murine lymphocytes. This medium is based on a basal medium supplemented with ⁇ - cyclodextrin, insulin, transferrin, albumin, low density lipoprotein, putrescine and alanine.
  • R-innmai- ⁇ of the Invention The present invention provides media for the culture of mammalian cells. The invention is more particularly pointed out in the appended claims and is described in its preferred embodiments in the following description. Detailed Description of the Invention The media of the invention are useful for the culture of mammalian cells.
  • the media of the invention have been found to be useful in the culture of Chinese hamster ovary (CHO) cells, and HAK cells, a baby hamster kidney cell line.
  • the media of the invention have been found not suitable for the culture of myeloma cell lines.
  • Cells may be grown in batch and continuous culture with the serum-frae media of the invention.
  • CHO cells grown in the media of the invention reach higher cell density and show increased recombinant product secretion when compared to CHO cells grown in a serum-containing medium.
  • the cell culture media of the invention are prepared by adding components to a basal medium designed for mammalian cell culture.
  • the media are prepared in accordance with standard procedures for preparing cell culture media.
  • Suitable basal media include standard mammalian cell culture media such as Ham's medium, Waymouth MB 752/1 medium. Eagle's medium, Williams E medium, 199 medium and derived edia of the types MEM and MEM ⁇ and any combinations of these media.
  • Other standard media used for the culture of mammalian cells are also suitable for use in the invention.
  • a preferred basal medium is the basal medium of Example 1.
  • the preferred basal medium supports cell growth and significantly reduces the size of cell clumps in the media during cell culture.
  • a yeast hydrolysate such as Yeastolate is added to the basal medium in the amount of from about 0.1 to about 10.0 grams per liter, preferably in an amount of about 5 grams per liter.
  • Albumin or dextran is added to the basal medium, in an amount of from about 0.1 to about 5.0 grams per liter.
  • bovine serum albumin or dextran having a molecular weight of about 500,000 is added to the basal medium.
  • Bovine serum albumin is preferably added in the amount of from about 0.1 to about 0.5 grams per liter.
  • Dextran having a molecular weight of about 500,000 such as Dextran T500 is preferably added to the basal medium in the amount from about 0.1 to about 1.0 grams per liter.
  • Insulin is added to the basal medium in the amount of from about 2.0 to about 20 milligrams per milliliter, preferably in the amount of about 10 milligrams per liter.
  • Transferrin or transferrin substitute is added to the basal medium in the amount of from about 0 to about 100.0 micrograms per milliliter.
  • Transferrin may be substituted in the medium with ferric fructose (from about 1.0 to about 10.0 milligrams per liter) , ferric citrate (from about 1.0 to about 100.0 milligrams per liter), or ferrous sulfate (from about 5.0 micromoles to about 200.0 micromoles per liter).
  • ferric fructose from about 1.0 to about 10.0 milligrams per liter
  • ferric citrate from about 1.0 to about 100.0 milligrams per liter
  • ferrous sulfate from about 5.0 micromoles to about 200.0 micromoles per liter.
  • a mixture of the fatty acids oleic, linoleic and linolenic are added to the basal medium in the ratio of oleic 0.6: linoleic 1: linole
  • oleic acid is preferably added to the basal medium in the amount of from about 0.012 to about 0.12 milligrams per liter; linoleic acid is preferably added to the basal medium in the amount of from about 0.2 to about 5.0 milligrams per liter; linolenic acid is added to the medium in the amount of from about 0.028 to about 0.7 milligrams per liter. Cholesterol is added to the basal medium in the amount of from about 0 to about 10.0 milligrams per liter.
  • CaCl 2 (anhydrous) is added to the basal medium in the amount of from about 0 to about 200 milligrams per liter, preferably in the amount of about 66.67 milligrams per liter.
  • Magnesium sulfate (MgSO (anhydrous) is added to the basal medium in the amount of from about 0 to about 100.0 milligrams per liter, preferably in the amount of about 24 milligrams per liter.
  • the pH of the medium is preferably from about 6.8 to about 7.4.
  • the osmolarity of the medium is preferably from about 280 to 360 milliosmoles.
  • the basal medium may be stored as a powder at 4 * C for one year.
  • the complete medium (basal medium with added supplements) in a liquid form may be stored at 4 ⁇ C for six months.
  • the components in the basal media are mixed and ball-mill ground to formulate a homogeneous powder.
  • the powdered media is then dispensed into 100L packets and stored at 4'C.
  • L-Alanine 41 300000 L-Arginine HCl 112.546700 L-Arginine FB 16.666000 L-Asparagine H20 28.336700 L-Aspartic Acid 24.433300 L-Cystine 2HC1 19.116600 L-Cysteine HC1.H20 45.040000 L-Cysteine FB 13.333300 L-Glutamic Acid 46.566700 L-Glutamine 292.000000 Glycine 35.833300
  • Vitamin B12 0.973300
  • Methyl Linoleate 0.010000 Vitamin A Acetate 0.033000
  • Medium MRl-3 contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan) , 500 mg/1 bovine serum albumin (BSA) (Armour, Kankakee, Illindis) 10 mg/1 bovine insulin (Waitaki, Toronto, Canada), 10 mg/1 bovine transferrin (Sigma Chemical Co., St.
  • the medium is prepared as follows:
  • Medium MR1-6 is contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan) , 500 mg/1 bovine serum albumin (Armour, Kankakee, Illinois) , 10 mg/1 bovine insulin (Waitaki, Toronto, Canada) , 10 mg/1 bovine transferrin (Sigma Chemical Co., St. Louis, Missouri), 0.12 mg/1 oleic acid (Ameresco, Cleveland, Ohio), 0.20 mg/1 linoleic acid (Ameresco), 0.028 mg/1 linolenic acid (Ameresco) , and 2 mg/1 cholesterol (Ameresco) .
  • the medium is prepared in the same way as medium MRl-3 in Example 2 except that steps 3 and 4 are omitted. In this medium no additional MgS0 4 or CaCl 2 is added.
  • Example 4 Preparation of Medium MRl-7.
  • Medium MRl-7 contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan), 1,000 mg/1 Dextran T-500 (Pharmacia, Piscataway, New Jersey), 10 mg/1 bovine insulin (Waitaki, Toronto, Canada) , 10 mg/1 bovine transferrin (Sigma Chemical Co, St.
  • Mediun MRl-7 is prepared in the same way as medium MRl-3 in Example 2 except that steps 3 and 4 are omitted and Dextran T-500 replaces bovine serum albumin in step 6. At step 6, 100 grams of Dextran T-500 are added and mixed until dissolved. • By.» ⁇ t ⁇ * ⁇ «» 5 Cell Culture
  • CHO cells transformed to produce soluble T4 lymphocytic cell receptor (cell line 37-80N) were cultured in four different media: serum containing medium Alpha (-) MEM/5% Fetal bovine serum (FBS) , and the media described in Examples 2, 3, and 4. 5 x 10 5 cells per milliliter were cultured for 7 days after seeding in 250 ml SP flasks with 150 ml of medium. Total cell number was determined by Coulter counter, and viability was determined by trypan blue dye exclusion using a hemocytometer. Concentration of ST4 was determined by an ELISA-based assay. At day two after seeding, the serum-free media showed greater number of cells than the serum containing medium.

Abstract

The invention provides serum-free media for the culture of mammalian cells comprising a synthetic basal medium designed for mammalian cell culture; about 0.1 to about 10 grams per liter hydrolyzed yeast; about 0.1 to about 5 grams per liter of dextran or albumin; about 2 to about 20 milligrams per liter insulin; 0 to about 100 milligrams per liter of a compound selected from the group consisting of transferrin, ferric fructose, ferrous citrate and ferrous sulfate; and a fatty acid component consisting of oleic acid, linoleic acid and linolenic acid in a ratio of about 0.6: 1: 0.14 milligrams of fatty acid per liter.

Description

MEDIUM FOR CULTURE OF MAMMALIAN CELLS
Field of the Invention
The present invention relates to the field of cell culture media. More particularly the invention relates to the field of mammalian cell culture media. Background of the Invention
Beyond a basal nutrient mixture of salts, sugars, amino acids, and vitamins, cells .in vitro have also been found to require for proliferation a supplement of poorly defined biological fluids or extracts. Because of availability and ease of storage, the most commonly used supplement is serum. The use of serum in cell culture media, however, has several disadvantages. Serum is comparatively expensive. Since serum is not a defined component, different lots of serum may vary in the concentration of compounds present and thus result in unpredictable culture growth. Serum may also be contaminated with viruses or mycoplasms. The protein in serum may complicate the purification of cell products from the culture medium. In efforts to overcome the disadvantages of serum containing medium, researchers have attempted to provide serum-free media by substituting defined or better characterized components for serum. Unfortunately, the complexity of serum and the differing growth requirements of different types of cells has made it difficult to provide such media. For reviews on serum-free media for mammalian cell culture see Rizzino et al. (1979) "Defined Media and the Determination of Nutritional and Hormonal Requirements of Mammalian Cells in Culture" Nutrition Reviews 37: 369-378; Barnes and Sato (1980) "Serum-free Cell Culture: a Unifying Approach*1, Cell .22.: 649-655; Barnes and Sato (1980) "Methods for Growth of Cultured Cells in Serum-Free Medium", Analyt. Biochem. 102: 255-270; and Bodeker et al. (1985) "A Screening Method To Develop Serum-Free Culture Media For Adherent Cell Lines", Develop. Biol. Standard. .6_0: 93-100.
U.S. Patent 4,786,599 issued November 22, 1988 to Chessebeuf and Padieu discloses a serum-free animal tissue culture medium containing a mixture of six fatty acids and albumin or dextran. The medium is particularly adapted for the primary culture of rat liver epithelial cells and possibly in the presence of hormones and/or growth factors, for obtaining cell lines, in particular myeloma and hybridoma cell lines.
Media for the serum-free culture of Chinese hamster ovary cells (CHO) have been reported. Gasser et al (1985) In Vitro Cellular & Developmental Biology 2.1: 588-592 discloses a serum-free medium for the culture of CHO cells. The serum- free medium is composed of a 1:1 mixture of Ham's F12 and modified Eagle's minimum essential media supplemented with transferrin, insulin, and selenium. Mendiaz et al. (1986) In Vitro Cellular & Developmental Biology .22.: 66-74 discloses a serum-free medium for the culture of CHO cells composed of a basal medium supplemented with insulin, and ferric sulfate or transferrin, selenium, trace elements, calcium chloride, glutamine, linoleic acid, non-essential amino acids, and insulin. Pietrzkowski et al (1988) Folia Histochemica et
Cytobiologica 2_6: 123-132 report a serum-free medium for the culture of chick embryo cells containing dextran. Pietrzkowski and Korohoda (1988) Folia Histochemica et Cytobiologica _\ 143-154 report a serum-free medium containing dextran for the culture of chick embryo fibroblasts. In these two publications, the dextran was added to the medium to enhance cell attachment and spreading. Ohmori (1988) Journal of Immunological Methods 112: 227-233 reports a serum-free medium which is able to support primary antibody responses by cultured murine lymphocytes. This medium is based on a basal medium supplemented with β- cyclodextrin, insulin, transferrin, albumin, low density lipoprotein, putrescine and alanine.
It is an object of the invention to provide serum- free media for the culture of mammalian cells. It is also object of the invention to provide serum-free media for the culture of mammalian cells transformed to produce recombinant products that increase product yield. It is yet another object of the invention to provide serum-free media for the culture of CHO cells. R-innmai-γ of the Invention The present invention provides media for the culture of mammalian cells. The invention is more particularly pointed out in the appended claims and is described in its preferred embodiments in the following description. Detailed Description of the Invention The media of the invention are useful for the culture of mammalian cells. The media of the invention have been found to be useful in the culture of Chinese hamster ovary (CHO) cells, and HAK cells, a baby hamster kidney cell line. The media of the invention have been found not suitable for the culture of myeloma cell lines.
Cells may be grown in batch and continuous culture with the serum-frae media of the invention. CHO cells grown in the media of the invention reach higher cell density and show increased recombinant product secretion when compared to CHO cells grown in a serum-containing medium.
The cell culture media of the invention are prepared by adding components to a basal medium designed for mammalian cell culture. The media are prepared in accordance with standard procedures for preparing cell culture media. Suitable basal media include standard mammalian cell culture media such as Ham's medium, Waymouth MB 752/1 medium. Eagle's medium, Williams E medium, 199 medium and derived edia of the types MEM and MEMα and any combinations of these media. Other standard media used for the culture of mammalian cells are also suitable for use in the invention. A preferred basal medium is the basal medium of Example 1. The preferred basal medium supports cell growth and significantly reduces the size of cell clumps in the media during cell culture.
A yeast hydrolysate such as Yeastolate is added to the basal medium in the amount of from about 0.1 to about 10.0 grams per liter, preferably in an amount of about 5 grams per liter.
Albumin or dextran is added to the basal medium, in an amount of from about 0.1 to about 5.0 grams per liter. Preferably either bovine serum albumin or dextran having a molecular weight of about 500,000 is added to the basal medium. Bovine serum albumin is preferably added in the amount of from about 0.1 to about 0.5 grams per liter. Dextran having a molecular weight of about 500,000 such as Dextran T500 is preferably added to the basal medium in the amount from about 0.1 to about 1.0 grams per liter. Insulin is added to the basal medium in the amount of from about 2.0 to about 20 milligrams per milliliter, preferably in the amount of about 10 milligrams per liter.
Transferrin or transferrin substitute is added to the basal medium in the amount of from about 0 to about 100.0 micrograms per milliliter. Transferrin may be substituted in the medium with ferric fructose (from about 1.0 to about 10.0 milligrams per liter) , ferric citrate (from about 1.0 to about 100.0 milligrams per liter), or ferrous sulfate (from about 5.0 micromoles to about 200.0 micromoles per liter). A mixture of the fatty acids oleic, linoleic and linolenic are added to the basal medium in the ratio of oleic 0.6: linoleic 1: linolenic 0.14 milligrams per liter of medium. In preferred embodiments of the invention, keeping this ratio of fatty acids, oleic acid is preferably added to the basal medium in the amount of from about 0.012 to about 0.12 milligrams per liter; linoleic acid is preferably added to the basal medium in the amount of from about 0.2 to about 5.0 milligrams per liter; linolenic acid is added to the medium in the amount of from about 0.028 to about 0.7 milligrams per liter. Cholesterol is added to the basal medium in the amount of from about 0 to about 10.0 milligrams per liter.
In a preferred embodiment of the invention which is described in further detail in Example 2, calcium chloride
(CaCl2) (anhydrous) is added to the basal medium in the amount of from about 0 to about 200 milligrams per liter, preferably in the amount of about 66.67 milligrams per liter. Magnesium sulfate (MgSO (anhydrous) is added to the basal medium in the amount of from about 0 to about 100.0 milligrams per liter, preferably in the amount of about 24 milligrams per liter.
The pH of the medium is preferably from about 6.8 to about 7.4. The osmolarity of the medium is preferably from about 280 to 360 milliosmoles.
The basal medium may be stored as a powder at 4*C for one year. The complete medium (basal medium with added supplements) in a liquid form may be stored at 4βC for six months.
Preferred embodiments of the invention are described in the following Examples. Example 1 Preparation of Basal Medium
The components in the basal media are mixed and ball-mill ground to formulate a homogeneous powder. The powdered media is then dispensed into 100L packets and stored at 4'C.
BASAL MEDIUM COMPONENTS; MR1 SERUM-FREE MEDIA COMPONENTS milligrams/1iter
INORGANIC SALTS/TRACE ELEMENTS
NaCl
KCL
NaH2PO4.H20
Na2HP04
MgC12 6H20
MgS04 (anhydrous)
CUSO4.5H20
Fe(NO3)3.9H20
FeSO4.7H20
ZnSO4.7H20
MnC12.4H20
Na2Se03 (anhyd)
Figure imgf000008_0001
AMINO ACIDS
L-Alanine 41. 300000 L-Arginine HCl 112.546700 L-Arginine FB 16.666000 L-Asparagine H20 28.336700 L-Aspartic Acid 24.433300 L-Cystine 2HC1 19.116600 L-Cysteine HC1.H20 45.040000 L-Cysteine FB 13.333300 L-Glutamic Acid 46.566700 L-Glutamine 292.000000 Glycine 35.833300
L-Histidine HC1.H20 20.986700 L-Histidine FB 5.000000 L-Isoleucine 35.480000 L-Leucine 46.833300 L-Lysine HCl 65.486600 L-Methionine 11.493300 L-Phenylalanine 20.653300 L-Proline 34.833300 L-Serine 15.166700 L-Threonine 33.300000 L-Tryptophan 7.346700 L-Tyrosine 2Na2H20 36.776700 L-Valine 35.900000
VITAMINS/MISC. COMPONENTS
Dextrose 4500.000000
Putrescine 2HC1 0.053700
Sodium Pyruvate 81.666700
Ascorbic Acid 17.333300
Biotin 0.202400
D-Calcium Pantothenate • 0.160000
Sodium Pantothenate 0.337330 -7-
Choline Chloride 5.486700
Folic Acid 1.100000 i-Inositol 7.333300
Nicotinamide 0.679000 Na2 alpha Tocopherol P04 0.003300
Glutathione (Reduced) 0.016700
Menadione Na Bisulfite 0.003300
Pyridoxine HCl 0.020700
Pyridoxal HCl 0.666700 Riboflavin 0.079300
Thiamine HCl 0.780000
Vitamin B12 0.973300
Calciferol 0.033300
Methyl Linoleate 0.010000 Vitamin A Acetate 0.033000
Linoleic Acid 0.028000
Lipoic Acid 0.136700
Preparation of Basal Medium - for a final volume of 100L Ninety liters of deionized-distilled water is measured into an appropriate mixing vessel. One 100L packet of ball-mill ground powdered media (see above) is added. The pH of the medium is adjusted to 7.2 using IN HCl. The volume of the medium is brought to 100L by the addition of water. The medium may then be sterilized by membrane filtration using a 0.2 micron cellulose acetate filter. Example 2 Preparation of Medium MRl-3
Medium MRl-3 contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan) , 500 mg/1 bovine serum albumin (BSA) (Armour, Kankakee, Illindis) 10 mg/1 bovine insulin (Waitaki, Toronto, Canada), 10 mg/1 bovine transferrin (Sigma Chemical Co., St. Louis, Missouri), 0.12 mg/1 oleic acid (Ameresco, Cleveland, Ohio), 0.20 mg/1 linoleic acid (Ameresco), 0.028 mg/1 linolenic acid (Ameresco) , 2 mg/1 cholesterol (Ameresco) , 66.67 mg/1 anhydrous calcium chloride, and 24 mg/1 anhydrous magnesium sulfate. The medium is prepared as follows:
For a final volume of 100L
1. Measure 90 liters of deionized-distilled water into an appropriate mixing vessel. 2. Add one 100L packet of ball-mill ground powdered media (from Example 1) .
3. Add 2.4 grams of MgS04 (anhydrous) and mix until dissolved.
4. Add 6.7 grams of CaCl2 (anhydrous) and mix until dissolved.
5. Add 500 grams of TC Yeastolate, mix until dissolved.
6. Add 50 grams of BSA, mix until dissolved.
7. Add 220 grams of NaHC03, mix until dissolved. 8. Add 1 gram of insulin, 1 gram of transferrin (or 100 ml of ferric fructose) and mix until dissolved.
9. Dissolve 12 mg of Oleic acid, 20 mg of Linoleic acid, 2.8 mg of Linolenic acid, and 200 mg of cholesterol in 100 mis of absolute ethanol, and add this fatty acid mix to the mixing vessel.
10. Adjust the pH to 7.2 using IN HCl.
11. Bring the volume to 100 liters and mix thoroughly.
12. Filter sterilize using a 0.2 micron cellulose acetate filter. 13. Check osmolarity and record.
14. Store at 4βC for up to six months.
Example 3 Preparation of Medium MR1-6
Medium MR1-6 is contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan) , 500 mg/1 bovine serum albumin (Armour, Kankakee, Illinois) , 10 mg/1 bovine insulin (Waitaki, Toronto, Canada) , 10 mg/1 bovine transferrin (Sigma Chemical Co., St. Louis, Missouri), 0.12 mg/1 oleic acid (Ameresco, Cleveland, Ohio), 0.20 mg/1 linoleic acid (Ameresco), 0.028 mg/1 linolenic acid (Ameresco) , and 2 mg/1 cholesterol (Ameresco) . The medium is prepared in the same way as medium MRl-3 in Example 2 except that steps 3 and 4 are omitted. In this medium no additional MgS04 or CaCl2 is added. Example 4 Preparation of Medium MRl-7. Medium MRl-7 contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan), 1,000 mg/1 Dextran T-500 (Pharmacia, Piscataway, New Jersey), 10 mg/1 bovine insulin (Waitaki, Toronto, Canada) , 10 mg/1 bovine transferrin (Sigma Chemical Co, St. Louis, Missouri) , 0.12 mg/1 oleic acid (Ameresco, Cleveland, Ohio), 0.20 mg/1 linoleic acid (Ameresco), 0.028 mg/1 linolenic acid (Ameresco) , and 2 mg/1 cholesterol (Ameresco) . Mediun MRl-7 is prepared in the same way as medium MRl-3 in Example 2 except that steps 3 and 4 are omitted and Dextran T-500 replaces bovine serum albumin in step 6. At step 6, 100 grams of Dextran T-500 are added and mixed until dissolved. By.»ιtι *ι«» 5 Cell Culture
CHO cells transformed to produce soluble T4, a soluble form of the T-4 lymphocytic cell receptor (cell line 37-80N) , were cultured in four different media: serum containing medium Alpha (-) MEM/5% Fetal bovine serum (FBS) , and the media described in Examples 2, 3, and 4. 5 x 105 cells per milliliter were cultured for 7 days after seeding in 250 ml SP flasks with 150 ml of medium. Total cell number was determined by Coulter counter, and viability was determined by trypan blue dye exclusion using a hemocytometer. Concentration of ST4 was determined by an ELISA-based assay. At day two after seeding, the serum-free media showed greater number of cells than the serum containing medium. In serum- containing medium, there were approximately 1.3 x 106 cells, whereas in the serum-free media there were approximately 1.6 x 106 cells. At days 3 through 7 significantly more cells were present in the serum-free media than the serum containing medium. At day 3, there were approximately 2.4 x 106 cells in the serum-containing medium and approximately 3.3 x 106 cells in the serum-free media. At day 4, the total number of cells in the serum-containing medium had dropped slightly to about 2.25 x 106 cells. In contrast, the number of cells in the serum-free media had increased to approximately 3.6 x 106 cells in MRl-7, 4.1 x 106 cells in MRl-3, and 4.3 x 106 cells in MR1-6. By day 7, the total number of cells in medium MR1- 7 had increased to approximately 4.0 x 106 cell, and the number of eels in the other media remained at levels comparable to the levels at day 4.
By three days post seeding, cells grown in the seru - free media produced significantly more sT4 than did cells grown in the serum containing medium. The difference in amount of sT4 product became more pronounced at days 4-7. At day 7, cells cultured in the serum free media produced from about 75 to 87 micrograms of sT4 per milliliter of medium, whereas cells cultured in the serum containing medium produced about 35 micrograms of sT4 per milliliter of medium.

Claims

Claims
1. A serum-free mammalian cell culture medium comprising:
(a) a synthetic basal medium designed for mammalian cell culture;
(b) about 0.1 to about 10 grams per liter hydrolyzed yeast;
(c) about 0.1 to about 5 grams per liter of dextran or albumin;
(d) about 2 to about 20 milligrams per liter insulin;
. (e) 0 to about 100 milligrams per liter of a compound selected from the group consisting of transferrin, ferric fructose, ferrous citrate and ferrous sulfate; and
(f) a fatty acid component consisting of oleic acid, linoleic acid and linolenic acid in a ratio of about 0.6 : 1 : 0.14 milligrams of fatty acid per liter.
2. The serum free mammalian cell culture medium of claim 1 further comprising 0 to about 10 milligrams per liter cholesterol.
3. The serum-free mammalian cell culture medium of claim 1 further comprising 0 to about 200 milligrams per liter anhydrous calcium chloride and 0 to about 100 milligrams per liter anhydrous magnesium sulfate.
4. The medium of claim 1 wherein said hydrolyzed yeast is present in the medium in the amount of about five grams per liter.
5. The medium of claim 1 wherein albumin is present in said medium in the amount of about 0.5 grams per liter.
6. The medium of claim 5 wherein said albumin is bovine serum albumin.
7. The medium of claim 1 wherein said dextran is present in said medium in the amount of about one gram per liter.
8. The medium of claim 7 wherein said dextran is dextran having a molecular weight of about 500,000.
9. The medium of claim 1 wherein said insulin is present in said medium in the amount of about 10 milligrams per liter.
10. The medium of claim 1 wherein transferrin is present in -li¬ the amount of about 10 milligrams per liter.
11. The medium of claim 1 wherein oleic acid is present in the amount of about 0.12 milligrams per liter; linoleic acid is present in the amount of about 0.20 milligrams per liter; and linolenic acid is present in the amount of about 0.028 milligrams per liter.
12. The medium of claim 2 wherein cholesterol is present in the amount of about two milligrams per liter.
13. The medium of claim 3 wherein said calcium chloride is present in the amount of about 66 to about 67 milligrams per liter; and magnesium sulfate is present in the amount of about 24 milligrams per liter.
14. A serum-free mammalian cell culture medium comprising:
(a) a synthetic basal medium designed for mammalian cell culture;
(b) about 5 grams per liter hydrolyzed yeast; (c) about 1 gram per liter of albumin;
(d) about 10 milligrams per liter insulin;
(e) about 10 milligrams per milliliter transferrin;
(f) a fatty acid component consisting of about 0.12 milligrams per liter oleic acid, about 0.20 milligrams per liter linoleic acid and about 0.028 milligrams per liter linolenic acid; and
(g) about 2 milligrams per liter cholesterol;
15. The medium of claim 14 further comprising about 66 to about 67 milligrams per liter anhydrous calcium chloride; and about 24 milligrams per liter anhydrous magnesium sulfate.
16. A serum-free mammalian cell culture medium comprising:
(a) a synthetic basal medium designed for mammalian cell culture;
(b) about 5 grams per liter hydrolyzed yeast; (c) about 1 gram per liter dextran having a molecular weight of about 500,000;
(d) about 10 milligrams per liter insulin;
(e) about 10 milligrams per liter transferrin;
(f) a fatty acid component consisting of about 0.12 milligrams per liter oleic acid, about 0.20 milligrams per liter linoleic acid and about 0.028 milligrams per liter linolenic acid; and
(g) about 2 milligrams per liter cholesterol.
PCT/US1991/006837 1990-09-25 1991-09-20 Medium for culture of mammalian cells WO1992005246A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU87348/91A AU662491B2 (en) 1990-09-25 1991-09-20 Medium for culture of mammalian cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58801790A 1990-09-25 1990-09-25
US588,017 1990-09-25

Publications (1)

Publication Number Publication Date
WO1992005246A1 true WO1992005246A1 (en) 1992-04-02

Family

ID=24352124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006837 WO1992005246A1 (en) 1990-09-25 1991-09-20 Medium for culture of mammalian cells

Country Status (11)

Country Link
EP (1) EP0550638A4 (en)
JP (1) JPH06500918A (en)
AU (1) AU662491B2 (en)
CA (1) CA2091443A1 (en)
IE (1) IE913345A1 (en)
MX (1) MX9101254A (en)
NZ (1) NZ239900A (en)
PT (1) PT99048B (en)
TW (1) TW240247B (en)
WO (1) WO1992005246A1 (en)
ZA (1) ZA917561B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008934A1 (en) * 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US5888815A (en) * 1993-11-01 1999-03-30 Pharmacia & Upjohn Aktiebolag Cell cultivation method and medium
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
WO2004022729A1 (en) * 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US6733746B2 (en) 1996-03-12 2004-05-11 Invitrogen Corporation Hematopoietic cell culture nutrient supplement
WO2005014800A1 (en) * 2003-08-08 2005-02-17 Cambridge Antibody Technology Limited Myeloma cell culture in transferrin-free low iron medium
US7189536B2 (en) 2000-11-23 2007-03-13 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US8361797B2 (en) 2003-08-08 2013-01-29 Medimmune Limited Myeloma cell culture in transferrin-free low iron medium
CN110343666A (en) * 2019-07-10 2019-10-18 通化东宝生物科技有限公司 A kind of supplemented medium and its preparation method and application of Chinese hamster ovary celI culture
WO2020127613A1 (en) * 2018-12-21 2020-06-25 Genfit In vitro model of liver steatosis and fibrosing non-alcoholic steatohepatitis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE501217C2 (en) * 1990-12-06 1994-12-12 Skandigen Ab Cell proliferation matrix and its use
JP4543402B2 (en) * 1996-10-10 2010-09-15 ライフ テクノロジーズ コーポレーション Animal cell culture medium containing plant-derived nutrients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786599A (en) * 1983-03-24 1988-11-22 Institut National De La Sante Et De La Recherche Medicale Serum-free animal cell culture medium and methods for the primary culture and production of cell lines using this medium
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5063157A (en) * 1988-01-18 1991-11-05 Boehringer Mannheim Gmbh Serum-free culture medium for mammalian cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4254489A (en) * 1989-10-03 1991-04-11 Ajinomoto Co., Inc. Method of induction and activation of cytotoxic t cells
ES2112866T3 (en) * 1990-09-25 1998-04-16 Smithkline Beecham Corp MEANS FOR CULTIVATION OF DROSOPHILA CELLS.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786599A (en) * 1983-03-24 1988-11-22 Institut National De La Sante Et De La Recherche Medicale Serum-free animal cell culture medium and methods for the primary culture and production of cell lines using this medium
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5063157A (en) * 1988-01-18 1991-11-05 Boehringer Mannheim Gmbh Serum-free culture medium for mammalian cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Analytical Biochemistry, Volume 102, issued 1980, BARNES et al, "Methods for Growth of Cultured Cells in Serum-Free Medium", pages 255-270, see entire document. *
Biotechnoly, Volumn 6, issued December 1988, B. MAIARELLA et al, "Large-Scale Insect Cell-Culture for Recombinant Protein Production", pages 1406-1410 see entire document. *
Cell, Volume 22, issued December 1980, D. BARNES et al, "Serum-Free Cell Culture: A Unifying Approach," pages 649-655, see entire document. *
In Vitro Cellular & Developmental Biology, Volume 21, No. 10, issued October 1985, F. GASSER et al, "Long-Term Multiplication of the Chinese Hamster Ovary (CHO) Cell Line in a Serum-Free Medium", pages 588-592, see entire document. *
See also references of EP0550638A4 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888815A (en) * 1993-11-01 1999-03-30 Pharmacia & Upjohn Aktiebolag Cell cultivation method and medium
US6733746B2 (en) 1996-03-12 2004-05-11 Invitrogen Corporation Hematopoietic cell culture nutrient supplement
EP2218775A1 (en) * 1996-08-30 2010-08-18 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US9321996B2 (en) 1996-08-30 2016-04-26 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
EP1482031A1 (en) * 1996-08-30 2004-12-01 Invitrogen Corporation Serum-free mammalian cell culture medium, and uses thereof
US8815573B2 (en) 1996-08-30 2014-08-26 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US8785194B2 (en) 1996-08-30 2014-07-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US8455246B2 (en) 1996-08-30 2013-06-04 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US8198084B2 (en) 1996-08-30 2012-06-12 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
WO1998008934A1 (en) * 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US7964396B2 (en) 2000-11-23 2011-06-21 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method
US7964395B2 (en) 2000-11-23 2011-06-21 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method
US8470598B2 (en) 2000-11-23 2013-06-25 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7964398B2 (en) 2000-11-23 2011-06-21 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method
US7335364B2 (en) 2000-11-23 2008-02-26 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7189536B2 (en) 2000-11-23 2007-03-13 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7459270B2 (en) 2000-11-23 2008-12-02 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US8236560B2 (en) 2000-11-23 2012-08-07 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
EA009008B1 (en) * 2002-09-05 2007-10-26 Бавариан Нордик А/С Method for amplification of poxviruses
US8329466B2 (en) 2002-09-05 2012-12-11 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
WO2004022729A1 (en) * 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7964397B2 (en) 2002-09-05 2011-06-21 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7695939B2 (en) 2002-09-05 2010-04-13 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US8673318B2 (en) 2002-09-05 2014-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US8361797B2 (en) 2003-08-08 2013-01-29 Medimmune Limited Myeloma cell culture in transferrin-free low iron medium
WO2005014800A1 (en) * 2003-08-08 2005-02-17 Cambridge Antibody Technology Limited Myeloma cell culture in transferrin-free low iron medium
JP2007501606A (en) * 2003-08-08 2007-02-01 ケンブリッジ アンチボディー テクノロジー リミテッド Myeloma cell culture in transferrin-free and low iron medium
WO2020127613A1 (en) * 2018-12-21 2020-06-25 Genfit In vitro model of liver steatosis and fibrosing non-alcoholic steatohepatitis
CN110343666A (en) * 2019-07-10 2019-10-18 通化东宝生物科技有限公司 A kind of supplemented medium and its preparation method and application of Chinese hamster ovary celI culture
CN110343666B (en) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 Feed supplement culture medium for CHO cell culture and preparation method and application thereof

Also Published As

Publication number Publication date
JPH06500918A (en) 1994-01-27
PT99048B (en) 1999-02-26
PT99048A (en) 1992-08-31
CA2091443A1 (en) 1992-03-26
IE913345A1 (en) 1992-02-25
ZA917561B (en) 1992-09-30
EP0550638A4 (en) 1993-12-08
MX9101254A (en) 1992-05-04
NZ239900A (en) 1993-09-27
EP0550638A1 (en) 1993-07-14
TW240247B (en) 1995-02-11
AU8734891A (en) 1992-04-15
AU662491B2 (en) 1995-09-07

Similar Documents

Publication Publication Date Title
AU662491B2 (en) Medium for culture of mammalian cells
EP0283942B1 (en) Basal nutrient medium for cell culture
US5122469A (en) Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
USRE30985E (en) Serum-free cell culture media
CN100362098C (en) Non-serum culture medium for multiple animal cell large-scale culture
US7462487B2 (en) Cell culture media
CN102827804B (en) Culture medium and method suitable for the amplification culture of Vero cell microcarrier suspension
CN101760442A (en) Serum-free medium for MDCK cell large-scale adherent culture and single-cell suspension culture
JP5431361B2 (en) Improved culture medium additive and method of using the same
CN106190950A (en) A kind of Chinese hamster ovary celI Serum-free and protein-free medium and preparation method thereof
CN111019883A (en) Serum-free and protein-free culture medium for CHO cell suspension culture and application thereof
CN111518768B (en) Low-serum culture medium suitable for LMH cell wall-attached culture and preparation method thereof
EP0659880B1 (en) Medium for culturing animal cells or antibody-producing cells
CN105567628B (en) A kind of low blood serum medium of the full culture mdck cell that suspends
CN111996161A (en) CHO cell serum-free and protein-free culture medium and application thereof
CN107435037A (en) A kind of serum free medium for bhk cell
CN113913368A (en) Serum-free medium suitable for CHO cell large-scale suspension amplification culture and preparation and application thereof
CN112063578A (en) Culture medium suitable for full-suspension cell culture and preparation method and application thereof
JPS5974982A (en) Cell growth medium replenishing agent and method of growing cell in vitro
JPH03180176A (en) Nutrient medium for cell culture
CN116790477A (en) Serum-free culture medium supporting CHO cell high-density culture and preparation method and application thereof
AU663060B2 (en) Media for culture of insect cells
CN109988741B (en) Serum substitute for cell culture, preparation method thereof, serum substitute composition for cell culture and cell culture medium
US5641678A (en) Serum-free culture medium for drosphila insect cells
JPH0568231B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2091443

Country of ref document: CA

Ref document number: 1991918096

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991918096

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1991918096

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991918096

Country of ref document: EP